Association of Mutations with Cancer Metastasis in Multiple Cancer Types

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2022 Jul 5

PMID 35789644

Authors

Chao Chen

Haozhen Liu

Qumiao Xu

Xiuqing Zhang

Feng Mu

Jixian Liu

Affiliations

Soon will be listed here.

Abstract

Metastasis is one of the characteristics of advanced cancer and the primary cause of cancer-related deaths from cancer, but the mechanism underlying metastasis is unclear, and there is a lack of metastasis markers. is a protein-coding gene involved in both signal transduction and cellular adhesion. It is also known as a tumor suppressor gene that inhibits cell malignant proliferation by inhibiting the STAT3 pathway. Recent studies have reported that is involved in the early metastatic seeding of colorectal cancer; however, the correlation between and metastasis in other types of cancer has not been revealed. A combined analysis using a dataset from the genomics evidence neoplasia information exchange (GENIE) and cBioPortal revealed that mutation is associated with poor prognosis in pan-cancer and non-small-cell lung cancer. The mutations of or "gene modules" containing are significantly enriched in patients with metastatic cancer in multiple cancers, suggesting that the mutations serve as potential biomarkers of cancer metastasis.

Citing Articles

A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice.

Yang H, Wang X, Blanco-Gomez A, He L, Garcia-Sancha N, Corchado-Cobos R EBioMedicine. 2024; 106:105260.

PMID: 39067134 PMC: 11338061. DOI: 10.1016/j.ebiom.2024.105260.

Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer.

Chaudhry Z, Boyadzhyan A, Sasaninia K, Rai V Antibodies (Basel). 2024; 13(2).

PMID: 38920970 PMC: 11200483. DOI: 10.3390/antib13020046.

Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.

Haugh A, Osorio R, Francois R, Tawil M, Tsai K, Tetzlaff M Cancers (Basel). 2024; 16(7).

PMID: 38611025 PMC: 11011039. DOI: 10.3390/cancers16071347.

Downregulation of PTPRT elevates the expression of survivin and promotes the proliferation, migration, and invasion of lung adenocarcinoma.

Chen C, Liu H, Li Y, Xu Q, Liu J BMC Cancer. 2024; 24(1):63.

PMID: 38216925 PMC: 10785488. DOI: 10.1186/s12885-024-11840-7.

Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort.

Shen F, Guo W, Song X, Wang B Diagn Pathol. 2023; 18(1):71.

PMID: 37301854 PMC: 10257305. DOI: 10.1186/s13000-023-01349-1.

References

Harada D, Takigawa N, Kiura K . The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2014; 6(2):708-22. PMC: 4074799. DOI: 10.3390/cancers6020708. View

Hoof I, Peters B, Sidney J, Pedersen L, Sette A, Lund O . NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2008; 61(1):1-13. PMC: 3319061. DOI: 10.1007/s00251-008-0341-z. View

Peters B, Sette A . Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics. 2005; 6:132. PMC: 1173087. DOI: 10.1186/1471-2105-6-132. View

Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M . NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008; 36(Web Server issue):W509-12. PMC: 2447772. DOI: 10.1093/nar/gkn202. View

Hsu H, Lapke N, Chen S, Lu Y, Jhou R, Yeh C . and Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2018; 10(9). PMC: 6162606. DOI: 10.3390/cancers10090314. View

Lui V, Peyser N, Ng P, Hritz J, Zeng Y, Lu Y . Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014; 111(3):1114-9. PMC: 3903220. DOI: 10.1073/pnas.1319551111. View

Zhang W, Shi F, Kong Y, Li Y, Sheng C, Wang S . Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer. Cancer Med. 2021; 11(3):676-691. PMC: 8817076. DOI: 10.1002/cam4.4472. View

Liu G, Li D, Li Z, Qiu S, Li W, Chao C . PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity. Gigascience. 2017; 6(5):1-11. PMC: 5467046. DOI: 10.1093/gigascience/gix017. View

Wang Z, Shen D, Parsons D, Bardelli A, Sager J, Szabo S . Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004; 304(5674):1164-6. DOI: 10.1126/science.1096096. View

10.

Peyser N, Freilino M, Wang L, Zeng Y, Li H, Johnson D . Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. 2015; 35(9):1163-9. PMC: 4651851. DOI: 10.1038/onc.2015.171. View

11.

Zhang H, Lund O, Nielsen M . The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding. Bioinformatics. 2009; 25(10):1293-9. PMC: 2732311. DOI: 10.1093/bioinformatics/btp137. View

12.

Chen C, Shi C, Huang X, Zheng J, Zhu Z, Li Q . Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma. Sci Rep. 2019; 9(1):13995. PMC: 6769015. DOI: 10.1038/s41598-019-50171-7. View

13.

Turajlic S, Swanton C . Metastasis as an evolutionary process. Science. 2016; 352(6282):169-75. DOI: 10.1126/science.aaf2784. View

14.

Malekzadeh P, Pasetto A, Robbins P, Parkhurst M, Paria B, Jia L . Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 2019; 129(3):1109-1114. PMC: 6391139. DOI: 10.1172/JCI123791. View

15.

Yu J, Becka S, Zhang P, Zhang X, Brady-Kalnay S, Wang Z . Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion. Mol Cancer Res. 2008; 6(7):1106-13. PMC: 2614372. DOI: 10.1158/1541-7786.MCR-07-2123. View

16.

Bourgonje A, Verrijp K, Schepens J, Navis A, Piepers J, Palmen C . Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma. Acta Neuropathol Commun. 2016; 4(1):96. PMC: 5009684. DOI: 10.1186/s40478-016-0372-x. View

17.

Hause R, Pritchard C, Shendure J, Salipante S . Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016; 22(11):1342-1350. DOI: 10.1038/nm.4191. View

18.

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

19.

Dudley J, Lin M, Le D, Eshleman J . Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016; 22(4):813-20. DOI: 10.1158/1078-0432.CCR-15-1678. View

20.

Li L, Xu F, Xie P, Yuan L, Zhou M . PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer. Biomed Res Int. 2021; 2021:3301402. PMC: 8370817. DOI: 10.1155/2021/3301402. View